Biocytogen

Biocytogen is a preclinical-stage biotechnology company providing critical tools and services for drug discovery, primarily through its genetically engineered mouse model platforms. The company's core offerings include its RenMice platforms, which generate fully humanized antibodies, and a suite of custom and off-the-shelf animal models for target validation and efficacy studies. By serving as a research enabler for pharmaceutical and biotech companies, Biocytogen operates a platform-and-services business model aimed at de-risking early-stage therapeutic development. Its strategic position in Boston provides access to a dense network of life sciences talent and potential partners.

Proprietary genetically engineered mouse platforms including RenMice (RenMab, RenLite, RenNano) for fully human antibody discovery, and extensive capabilities in custom mouse model generation using CRISPR/Cas9 and ES cell technologies.

Biocytogen competes with large preclinical contract research organizations (CROs) like Charles River and Taconic in animal models, and with companies like GenScript and Ablexis in antibody discovery. Its differentiation lies in the scale and sophistication of its chromosome-engineered RenMice and its integrated, end-to-end service model.